Amgen has announced job cuts of 2200?2600, equating to a loss of 12?14% of its workforce.
Amgen has announced job cuts of 2200–2600, equating to a loss of 12–14% of its workforce. This is to offset the company's recent difficulties with the sales of its anaemia blockbusters. The cuts are due for completion by next year and in combination with other drives to promote operational efficiency (such as closing certain production facilities) are anticipated to reap pretax savings of in excess of $1 billion in 2008. The company hopes that this will enable it to maintain "industry-leading levels" of investment in R&D.
Scrutiny around the firm's two top selling drugs Aranesp (darbopoietin alfa) and Epogen has intensified over recent months, with its sales for anaemia products declining 6% in the second quarter of the year. This was mainly because of Aranesp, which suffered a 19% decrease from the same quarter last year. A change in the drug's labelling, implemented by FDA following safety concerns of erythropoietin stimulating agents, affected sales.
Kevin Sharer, Amgen's chairman and chief executive officer said: "Recent changes in coverage rules and adjustments to Amgen's FDA approved labels for EPOGEN and Aranesp have and will adversely affect Amgen's revenue. The initiatives announced respond to that new reality by taking account of reduced revenues and appropriately lowering costs across the company." He added that the company would continue to support its research efforts for the development of new medicines for grievously ill patients. Furthermore, the Center for Medicare and Medicaid Services' plan to set new guidelines for erythropoietin stimulating agents will drastically cut reimbursements and prescriptions of anaemia drugs, which could have further impact on Aranesp's sales.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.